Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00263276 · ClinicalTrials.gov registry record · Phase 2
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 389
- Enrollment target
NCT00263276 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 389 participants.
The verdict
NCT00263276, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 389 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise and should not have previously been treated for their diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be studied
Interventions
- DRUG dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00263276
The ClinicalTrials.gov registry entry for NCT00263276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 389 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dapagliflozin is the first listed.
NCT00263276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00263276 about?
NCT00263276 is a clinical study titled "A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus". The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise ...
What is the current status of trial NCT00263276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 389 participants. The study started on 2005-12. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00263276?
The interventions under investigation include: dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT00263276?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.